Effect of cyclosporin A on alveolar bone homeostasis in a rat periodontitis model

Journal of Periodontal Research

Volumn 39, Issue 3, 2004, Pages 143-148

  Nassar, C A ^a   Nassar, P O ^a   Abi Rached, R S G ^a   Holzhausen, M ^a   Marcantonio Jr , E ^a   Spolidorio, L C ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

Alveolar bone; Animal studies; Bone loss etiology; Cyclosporin A adverse effects; Digital radiography

Indexed keywords

ALKALINE PHOSPHATASE; CALCIUM; CYCLOSPORIN A; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT;

ALKALINE PHOSPHATASE BLOOD LEVEL; ALVEOLAR BONE; ANIMAL MODEL; ARTICLE; BODY WEIGHT; BONE MARROW; CALCIUM BLOOD LEVEL; CONTROL GROUP; CONTROLLED STUDY; COTTON; DRUG EFFECT; ENAMEL; EXPERIMENTAL MODEL; EXPERIMENTAL RAT; HISTOLOGY; HOMEOSTASIS; MEASUREMENT; MOLAR TOOTH; NONHUMAN; OSTEOCLAST; PERIODONTITIS; RADIOGRAPHY; RAT; SERUM; STATISTICAL SIGNIFICANCE; STEREOMETRY; ANALYSIS OF VARIANCE; ANIMAL; BLOOD; BONE DENSITY; BONE REMODELING; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; LIGATION; NONPARAMETRIC TEST; OSTEOLYSIS; SPRAGUE DAWLEY RAT;

ALKALINE PHOSPHATASE; ALVEOLAR BONE LOSS; ANALYSIS OF VARIANCE; ANIMALS; BONE DENSITY; BONE REMODELING; CALCIUM; CYCLOSPORINE; DISEASE MODELS, ANIMAL; IMMUNOSUPPRESSIVE AGENTS; LIGATION; PERIODONTITIS; RATS; RATS, SPRAGUE-DAWLEY; STATISTICS, NONPARAMETRIC;

EID: 2542439573     PISSN: 00223484     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0765.2004.00739.x     Document Type: Article

References (51)

1. Faulds D, Goa KL, Benfield P. Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders. Drugs 1993;45:953-1040.
2. Schreiber SL. Chemistry and biology of the immunophilins and their immunosuppressive ligands. Science 1991;251:283-287.
3. Horl WH, Riegel W, Wanner C et al. Endocrine and metabolic abnormalities following kidney transplantation. Klin Wochenschr 1989;67:907-918.
4. Lynn M, Abreo K, Zibari G, McDonald J. End-stage renal disease in liver transplants. Clin Transplant 2001;6:66-69.
5. Koomans HA, Ligtenberg G. Mechanisms and consequences of arterial hypertension after renal transplantation. Transplantation 2001;72:9-12.
6. Marshall RI, Bartold PM. A clinical review of drug-induced gingival overgrowths. Aust Dent J 1999;44:219-232.
7. Spolidorio LC, Merzel J, Vilialba H, Vargas PA, Coletta RD, Almeida P. Morphometric evaluation of gingival overgrowth and regression caused by zcyclosporin in rats. J Periodont Res 2001;36:384-389.
8. Canalis E, McCarthy T, Centrella M. Growth factors and the regulation of bone remodeling. J Clin Invest 1988;81:277-281.
9. Cvetkovic M, Mann GN, Romero DF et al. The deleterious effects of long-term cyclosporine A, cyclosporine G, and FK506 on bone mineral metabolism in vivo. Transplantation 1994;57:1231-1237.
10. Bennett WM, Norman DJ. Action and toxicity of cyclosporine. Annu Rev Med 1986;37:215-224.
11. Esa AH, Paxman DG, Noga SJ, Hess AD. Sensitivity of monocyte subpopulations to cyclosporine. Arachidonate metabolism and in vitro antigen presentation. Transplant Proc 1988;20:80-86.
12. Whisler RL, Lindsey JA, Proctor KV, Morisaki N, Cornwell DG. Characteristics of cyclosporine induction of increased prostaglandin levels from human peripheral blood monocytes. Transplantation 1984;38:377-388.
13. Schultze G, Stahl P, Nigam S, Sieber G, Offermann G, Molzahn M. Effect of cyclosporine on the generation of prostanoids by cultured peripheral lymphocytes. Transplant Proc 1984;16:1214-1217.
14. Lindsey JA, Morisaki N, Stitts JM, Zager RA, Cornwell DG. Fatty acid metabolism and cell proliferation. IV. Effect of prostanoid biosynthesis from endogenous fatty acid release with cyclosporin-A. Lipids 1983;18:566-369.
15. Wondimu B, Modeer T. Cyclosporin A upregulates prostaglandin E2 production in human gingival fibroblasts challenged with tumor necrosis factor alpha in vitro. J Oral Pathol Med 1997;26:11-16.
16. Schwartz Z, Goultschin J, Dean DD, Boyan BD. Mechanisms of alveolar bone destruction in periodontitis. Periodontol 2000 1997;14:158-172.
17. Orcel P, Bielakoff J, Modrowski D, Miravet L, de Vernejoul MC. Cyclosporin A induces in vivo inhibition of resorption and stimulation of formation in rat bone. J Bone Miner Res 1989;4:387-391.
18. Dougados M, Awada H, Amor B. Cyclosporin in rheumatoid arthritis: a double blind, placebo controlled study in 52 patients. Ann Rheum Dis 1988;47:127-133.
19. Muchmore JS, Cooper DKYeY, Schlegel VT, Zuhdi N. Loss of vertebral bone density in heart transplant patients. Transplant Proc 1991;23:1184-1185.
20. Rich GM, Mudge GH, Laffel GL, LeBoff MS. Cyclosporine A and prednisone-associated osteoporosis in heart transplant recipients. J Heart Lung Transplant 1992;11:950-958.
21. Negri AL, Plantalech LC, Russo Picasso MF, Otero A, Sarli M. Post-transplantation osteoporosis. Medicina (B Aires) 1999;59:777-786.
22. Fu E, Hsieh YD, Nieh S, Wikesjo UM, Liu D. Effects of cyclosporin A on alveolar bone: an experimental study in the rat. J Periodontol 1999;70:189-194.
23. Shen EC, Fu E, Hsieh YD. Effects of cyclosporin A on dental alveolar bone: a histomorphometric study in rats. J Periodontol 2001;72:659-665.
24. Fu E, Hsieh YD, Shen EC, Nieh S, Mao TK, Chiang CY. Cyclosporin-induced gingival overgrowth at the newly formed edentulous ridge in rats: a morphological and histometric evaluation. J Periodontol 2001;72:889-894.
25. Sallay K, Sanavi F, Ring I, Pham P, Behling UH, Nowotny A. Alveolar bone destruction in the immunosuppressed rat. J Periodont Res 1982;17:263-274.
26. Holzhausen M, Rossa Jr. C, Marcantonio Jr E, Nassar PO, Spolidorio DMP, Spolidorio LC. Effect of selective cyclooxygenase-2 inhibition on the development of ligature induced periodontitis in rats. J Periodontol 2002;73:1030-1036.
27. Wassef R, Cohen Z, Langer B. Pharmacokinetic profiles of cyclosporin in rats. Influence of route of administration and dosage. Transplantation 1985;40:489-493.
28. Delesse MA. Procedé mécanique pour determiner la composition des roches. CR Acad Sci 1848;25:544.
29. Weibel ER. Selection of the best method in stereology. J Microsc 1974;100:261-269.
30. Johnson DA, Behling UH, Lai CH, Listgarten M, Socransky S, Nowotny A. Role of bacterial products in periodontitis. II. Immune response in gnotobiotic rats monoinfected with Eikenella corrodens. Infect Immun 1978;19:246-253.
31. Nociti Jr. FH, Nogueira-Filho GR, Tramontina VA et al. Histometric evaluation of the effect of nicotine administration on periodontal breakdown: an in vivo study. J Periodont Res 2001;36:361-366.
32. Schlosberg M, Movsowitz C, Epstein S, Ismail F, Fallon MD, Thomas S. The effect of cyclosporin A administration and its withdrawal on bone mineral metabolism in the rat. Endocrinology 1989;124:2179-2184.
33. Movsowitz C, Epstein S, Fallon M, Ismail F, Thomas S. Cyclosporin-A in vivo produces severe osteopenia in the rat: effect of dose and duration of administration. Endocrinology 1988;123:2571-2577.
34. Rucinski B, Liu CC, Epstein S. Utilization of cyclosporine H to elucidate the possible mechanisms of cyclosporine A-induced osteopenia in the rat. Metabolism 1994;43:1114-1118.
35. Katz I, Li M, Joffe I et al. Influence of age on cyclosporin A-induced alterations in bone mineral metabolism in the rat in vivo. J Bone Miner Res 1994;9:59-67.
36. Klein L, Lemel MS, Wolfe MS, Shaffer J. Cyclosporin A does not affect the absolute rate of cortical bone resorption at the organ level in the growing rat. Calcif Tissue Int 1994;55:295-301.
37. Dieperink H, Kemp E, Leyssac PP, Starklint H. Cyclosporin A: effectiveness and toxicity in a rat model. Clin Nephrol 1986;25:546.
38. Stewart PJ, Stern PH. Cyclosporines: correlation of immunosuppressive activity and inhibition of bone resorption. Calcif Tissue Int 1989;45:222-226.
39. Chowdhury MH, Shen V, Dempster DW. Effects of cyclosporine A on chick osteoclasts in vitro. Calcif Tissue Int 1991;49:275-279.
40. Russell RG, Graveley R, Skjodt H. The effects of cyclosporin A on bone and cartilage. Br J Rheumatol 1993;1:42-46.
41. Cueto-Manzano AM, Konel S, Hutchison AJ et al. Bone loss in long-term renal transplantation: histopathology and densitometry analysis. Kidney Int 1999;55:2021-2029.
42. Kawana K, Takahashi M, Kushida K, Hoshino H, Sakata S, Inoue T. The effect of cyclosporin administration on bone metabolism in the rat evaluated by biochemical markers. J Endocrinol Invest 1996;19:499-504.
43. Buchinsky FJ, Ma Y, Mann GN et al. Bone mineral metabolism in T lymphocyte-deficient and -replete strains of rat. J Bone Miner Res 1995;10:1556-1565.
44. McCauley LK, Rosol TJ, Capen CC. Effects of cyclosporin A on rat osteoblasts (ROS 17/2.8 cells) in vitro. Calcif Tissue Int 1992;51:291-297.
45. Morton RS, Dongari-Bagtzoglou AI. Cyclooxygenase-2 is upregulated in inflamed gingival tissues. J Periodontol 2001;72:461-469.
46. Gemmell E, Marshall RI, Seymour GJ. Cytokines and prostaglandins in immune homeostasis and tissue destruction in periodontal disease. Periodontol 2000 1997;14:112-143.
47. Gallwitz WE, Mundy GR, Lee CH et al. 5-Lipoxygenase metabolites of arachidonic acid stimulate isolated osteoclasts to resorb calcified matrices. J Biol Chem 1993;268:10087-10094.
48. Taubman MA, Buckelew JM, Ebersole JL, Smith DJ. Periododontal bone loss and immune response to ovalbumin in germ free rats fed antigen-free diet with albumin. Infect Immun 1981;32:145-152.
49. Mason J. Renal side-effects of cyclosporin A. Br J Dermatol 1990;122:71-77.
50. Ryffel B. Cyclosporin. Toxicology - experimental studies. Prog Allergy 1986;38:181-197.
51. Wong MM, Rao LG, Ly H et al. Long-term effects of physiologic concentrations of dexamethasone on human bone-derived cells. J Bone Miner Res 1990;5:803-813.